BriaCell Presents Encouraging Data on Breast Cancer Immunotherapy
Event summary
- BriaCell will present three posters at the San Antonio Breast Cancer Symposium (SABCS) on December 10, 2025, detailing Phase 2 survival data and Phase 3 biomarker data.
- The Phase 3 trial of Bria-IMT+CPI in advanced metastatic breast cancer is ongoing, with an interim analysis expected in 1H2026.
- Pooled data from 116 patients suggests improved progression-free survival (PFS) in HR+/HER-2 and HER2-low subtypes.
- Analysis of 30 patients in Phase 1/2 studies indicates potential predictive biomarkers, including delayed type hypersensitivity (DTH) and Th1-biased cytokine signatures.
The big picture
BriaCell’s immunotherapy approach targets a significant unmet need in advanced breast cancer, a market with substantial revenue potential. The company's focus on biomarkers aligns with the broader trend towards precision medicine, which aims to tailor treatments based on individual patient characteristics. However, the success of Bria-IMT hinges on demonstrating a clear clinical benefit in the ongoing Phase 3 trial and establishing the predictive value of its identified biomarkers.
What we're watching
- Clinical Efficacy
- The interim analysis of the Phase 3 trial in 1H2026 will be critical in determining whether the observed survival benefits in earlier phases translate to a statistically significant outcome in a larger patient population.
- Biomarker Validation
- The utility of biomarkers like NLR and DTH in patient selection will need to be rigorously validated to ensure they accurately predict treatment response and avoid unnecessary exposure to therapy.
- Regulatory Pathway
- Successful validation of biomarkers could accelerate BriaCell’s regulatory pathway by enabling a more targeted and efficient clinical development program, but hinges on demonstrating clinical utility to regulators.
Related topics